|
1
|
Lehrer RI: Primate defensins. Nat Rev
Microbiol. 2:727–738. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pazgier M, Hoover DM, Yang D, Lu W and
Lubkowski J: Human beta-defensins. Cell Mol Life Sci. 63:1294–1313.
2006. View Article : Google Scholar
|
|
3
|
Rodriguez-Jimenez FJ, Krause A, Schulz S,
et al: Distribution of new human beta-defensin genes clustered on
chromosome 20 in functionally different segments of epididymis.
Genomics. 81:175–183. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schroder JM and Harder J: Human
beta-defensin-2. Int J Biochem Cell Biol. 31:645–651. 1999.
View Article : Google Scholar
|
|
5
|
Liu L, Wang L, Jia HP, et al: Structure
and mapping of the human beta-defensin HBD-2 gene and its
expression at sites of inflammation. Gene. 222:237–244. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hiratsuka T, Nakazato M, Date Y, et al:
Identification of human beta-defensin-2 in respiratory tract and
plasma and its increase in bacterial pneumonia. Biochem Biophys Res
Commun. 249:943–947. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bals R, Wang X, Wu Z, et al: Human
beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in
human lung. J Clin Invest. 102:874–880. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh PK, Jia HP, Wiles K, et al:
Production of beta-defensins by human airway epithelia. Proc Natl
Acad Sci USA. 95:14961–14966. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen CI, Schaller-Bals S, Paul KP, Wahn U
and Bals R: Beta-defensins and LL-37 in bronchoalveolar lavage
fluid of patients with cystic fibrosis. J Cyst Fibros. 3:45–50.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harder J, Bartels J, Christophers E and
Schröder JM: A peptide antibiotic from human skin. Nature.
387:8611997. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hall RM and Collis CM: Antibiotic
resistance in gram-negative bacteria: the role of gene cassettes
and integrons. Drug Resist Updat. 1:109–119. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Partridge SR: Analysis of antibiotic
resistance regions in Gram-negative bacteria. FEMS Microbiol Rev.
35:820–855. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boucher HW, Talbot GH, Bradley JS, et al:
Bad bugs, no drugs: no ESKAPE! An update from the Infectious
Diseases Society of America. Clin Infect Dis. 48:1–12. 2009.
|
|
14
|
Slama TG: Gram-negative antibiotic
resistance: there is a price to pay. Crit Care. 12(Suppl 4):
S42008. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peleg AY and Hooper DC: Hospital-acquired
infections due to gram-negative bacteria. N Engl J Med.
362:1804–1813. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mauldin PD, Salgado CD, Hansen IS, Durup
DT and Bosso JA: Attributable hospital cost and length of stay
associated with health care-associated infections caused by
antibiotic-resistant gram-negative bacteria. Antimicrob Agents
Chemother. 54:109–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Siegel RE: Emerging gram-negative
antibiotic resistance: daunting challenges, declining
sensitivities, and dire consequences. Respir Care. 53:471–479.
2008.PubMed/NCBI
|
|
18
|
Chopra I, Schofield C, Everett M, et al:
Treatment of health-care-associated infections caused by
Gram-negative bacteria: a consensus statement. Lancet Infect Dis.
8:133–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu B, Dong CY, Zhang F, Lin YM, Wu KF and
Ma XT: Synergistic antileukemia effect of combinational gene
therapy using murine beta-defensin 2 and IL-18 in L1210 murine
leukemia model. Gene Ther. 14:1181–1187. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yin C, Dang HN, Gazor F and Huang GT:
Mouse salivary glands and human beta-defensin-2 as a study model
for antimicrobial gene therapy: technical considerations. Int J
Antimicrob Agents. 28:352–360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harvey SA, Romanowski EG, Yates KA and
Gordon YJ: Adenovirus-directed ocular innate immunity: the role of
conjunctival defensin-like chemokines (IP-10, I-TAC) and phagocytic
human defensin-alpha. Invest Ophthalmol Vis Sci. 46:3657–3665.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meyerholz DK, Grubor B, Gallup JM, et al:
Adenovirus-mediated gene therapy enhances parainfluenza virus 3
infection in neonatal lambs. J Clin Microbiol. 42:4780–4787. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bals R, Weiner DJ, Moscioni AD, Meegalla
RL and Wilson JM: Augmentation of innate host defense by expression
of a cathelicidin antimicrobial peptide. Infect Immun.
67:6084–6089. 1999.PubMed/NCBI
|
|
24
|
Gaudreault E and Gosselin J: Leukotriene
B4 induces release of antimicrobial peptides in lungs of virally
infected mice. J Immunol. 180:6211–6221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alekseeva L, Huet D, Femenia F, et al:
Inducible expression of beta defensins by human respiratory
epithelial cells exposed to Aspergillus fumigatus organisms.
BMC Microbiol. 9:332009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krisanaprakornkit S, Kimball JR, Weinberg
A, Darveau RP, Bainbridge BW and Dale DA: Inducible expression of
human beta-defensin 2 by Fusobacterium nucleatum in oral
epithelial cells: multiple signaling pathways and role of commensal
bacteria in innate immunity and the epithelial barrier. Infect
Immun. 68:2907–2915. 2000.PubMed/NCBI
|
|
27
|
Liu AY, Destoumieux D, Wong AV, et al:
Human beta-defensin-2 production in keratinocytes is regulated by
interleukin-1, bacteria, and the state of differentiation. J Invest
Dermatol. 118:275–281. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanda N, Tada Y, Shimizu T and Watanabe S:
IL-12, IL-23, and IL-27 enhance human beta-defensin-2 production in
human keratinocytes. J Invest Dermatol. 38:1287–1296.
2008.PubMed/NCBI
|
|
29
|
Tsutsumi-Ishii Y and Nagaoka I: NF-kappa
B-mediated transcriptional regulation of human beta-defensin-2 gene
following lipopolysaccharide stimulation. J Leukoc Biol.
71:154–162. 2002.PubMed/NCBI
|
|
30
|
Yoon YM, Lee JY, Yoo D, et al: Bacteroides
fragilis enterotoxin induces human beta-defensin-2 expression in
intestinal epithelial cells via a mitogen-activated protein
kinase/I kappa B kinase/NF-kappa B-dependent pathway. Infect Immun.
78:2024–2033. 2010. View Article : Google Scholar
|
|
31
|
Wehkamp J, Harder J, Wehkamp K, et al:
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in
intestinal epithelial cells by Escherichia coli Nissle 1917:
a novel effect of a probiotic bacterium. Infect Immun.
72:5750–5758. 2004.PubMed/NCBI
|
|
32
|
Palkowitsch L, Marienfeld U, Brunner C,
Eitelhuber A, Krappmann D and Marienfeld RB: The
Ca2+-dependent phosphatase calcineurin controls the
formation of the Carma1-Bcl10-Malt1 complex during T cell
receptor-induced NF-kappaB activation. J Biol Chem. 286:7522–7534.
2011.PubMed/NCBI
|
|
33
|
Lavigne JP, Brunel JM, Chevalier J and
Pages JM: Squalamine, an original chemosensitizer to combat
antibiotic-resistant gram-negative bacteria. J Antimicrob
Chemother. 65:799–801. 2010. View Article : Google Scholar : PubMed/NCBI
|
